Psychiatry AtlasMedication guide · United States

Sleep medicine

Eszopiclone (Lunesta)

Generic name
eszopiclone
Brand names
Lunesta
Medication class
Sleep medicine
Forms covered
Lunesta oral tablets

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

FDA Boxed Warning

Lunesta 1 mg, 2 mg and 3 mg oral tablets.

Eszopiclone can cause sleepwalking, sleep-driving and other activities while not fully awake. These complex sleep behaviors can cause serious injury or death. Stop eszopiclone immediately and contact the prescriber if they occur.

Eszopiclone (Lunesta) helps adults fall asleep and stay asleep. It carries a boxed warning for serious injury or death from activities performed while not fully awake.

What to expect: The medicine is intended to improve sleep on the nights it is taken.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Insomnia with sleep-onset and sleep-maintenance benefit — Adults. Pediatric safety and efficacy are not established.Lunesta oral tablets.

What should I expect?

The medicine is intended to improve sleep on the nights it is taken. Next-day coordination and alertness can still be impaired, including when you feel that you slept well.

If sleep does not improve within 7–10 days or worsens, contact the prescriber rather than increasing the dose. Ongoing treatment should be reviewed for both sleep benefit and daytime safety.

How do I take it safely?

Take immediately before bed with 7–8 hours available. Avoid taking it with or immediately after a heavy, high-fat meal. Do not stay up doing activities afterward, repeat the dose or add another sleep medicine.

Older or frail adults, severe liver impairment and some potent interacting medicines have a lower maximum dose. Kidney impairment does not require the same adjustment. Follow the prescribed dose.

Avoid alcohol and unreviewed sedatives, including opioids. Have antifungals, antibiotics, seizure medicines and other interacting treatments checked. People taking 3 mg are cautioned against driving or hazardous activities the next day.

Do not use after prior Lunesta-related complex sleep behavior or allergy. Discuss breathing disease, liver disease, depression, suicidal thinking, falls and substance-use history.

Stop and contact the prescriber immediately if sleepwalking, sleep-driving or other behavior while not fully awake occurs. Unusual thinking, hallucinations or worsening mood also need prompt assessment.

Skip a missed dose if 7–8 hours are no longer available; never double or take a daytime catch-up dose. Regular use may need an individual stopping plan to limit withdrawal. Store securely and never share.

Discuss pregnancy or breastfeeding because available human data are limited. Pediatric use is not established.

What side effects should I know about?

  • Unpleasant taste, headache, sleepiness, dizziness and dry mouth.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • FDA boxed warning: complex sleep behaviors, including sleepwalking, sleep-driving and other activities while not fully awake, can cause serious injury or death. They can occur after the first or a later dose, even at recommended doses and without alcohol. Stop the medicine immediately and contact the prescriber if this occurs.
  • New suicidal thoughts or a severe mood or behavior change needs immediate clinical contact; get emergency help if someone cannot stay safe.
  • Report severe confusion, hallucinations or unusual behavior promptly. Next-day impairment may occur even when you feel awake; do not drive when impaired.
  • Get emergency help for trouble breathing, swelling of the tongue or throat, collapse, a seizure or inability to wake. Suspected overdose needs immediate poison-center or emergency advice; do not wait for symptoms.

What else should I know to stay safe?

  • Do not use after Lunesta-related complex sleep behavior or allergy. Review breathing disease, liver disease, depression, falls and substance-use history. Older or frail adults, severe liver impairment and certain potent interacting medicines require a lower maximum dose.
  • Avoid alcohol and unreviewed sedatives, opioids or other sleep medicines. Have enzyme-blocking or enzyme-inducing medicines checked. The 3-mg dose carries a specific next-day driving caution; regular use may need an individual gradual stopping plan. Store securely and never share.
  • Discuss pregnancy and breastfeeding because human evidence is limited. Pediatric safety and effectiveness are not established.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • An unpleasant taste is a recognized effect of eszopiclone; mention it if it makes treatment difficult.
  • The 3-mg dose carries a specific next-day driving caution. More sleep benefit can come with a meaningful alertness trade-off.
  • Being chemically different from benzodiazepines does not remove misuse, dependence or withdrawal risks.

How does it work?

Eszopiclone’s sleep-promoting effect is thought to involve GABA, a chemical messenger that helps restrain nerve-cell activity. It acts at receiving structures associated with this messenger, although the precise steps that produce sleep are not fully understood. Its effects can include both sleepiness and reduced alertness after waking.

Explore more in Brain & Science: Benzodiazepines and GABA: Alprazolam.

How was this medicine developed?

Lunesta received FDA approval in 2004, with studies examining sleep onset and maintenance. Subsequent safety labeling emphasized next-day impairment and complex sleep behaviors that can cause serious injury.

How do I say the name?

Eszopiclone: es-ZOE-pi-clone. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Lunesta: current prescribing information
  2. Lunesta: FDA approval history
  3. Eszopiclone: patient medicine information
  4. Lunesta: Package Insert / Prescribing Information / MOA
  5. Lunesta: FDA prescribing information
  6. Ambien: current prescribing information
  7. Eszopiclone: verified neutral parent, PubChem CID 969472
  8. ISMP List of Confused Drug Names
  9. Frequently Asked Questions about Labeling for Prescription Medicines | FDA
  10. Schizophrenia
  11. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top